Serum concentrations of mood stabilizers are associated with memory, but not other cognitive domains in psychosis spectrum disorders; explorative analyses in a naturalistic setting

International Journal of Bipolar Disorders

Table 1 Demographic data, diagnosis, and psychopharmacological treatment

	N	%
Total number of participants	217	100
Number of males	89	41.0
Diagnosis
Schizophrenia and other psychotic disorders^a	50	23.0
Schizophrenia	21	9.7
Schizophreniform disorder	2	0.9
Schizoaffective disorder	17	7.8
Delusional disorder	1	0.5
Brief psychotic disorder	1	0.5
Psychotic disorder NOS	8	3.7
Bipolar disorders^a	167	77.0
Bipolar I disorder	117	53.9
Bipolar II disorder	42	19.4
Bipolar disorder NOS	8	3.7
Main anticonvulsant drug^b
Lamotrigine	109	50.2
Valproate	62	28.6
Lithium^c	58	26.7
More than one mood stabilizer^d	17	7.8
Other psychotropic drugs
Use of other anticonvulsant drugs	11	5.1
Use of antipsychotics	128	59.0
Use of antidepressants	86	39.6
Use of sedatives^e	35	16.1

BD bipolar disorder, IDS inventory of depressive symptomatology, IQR interquartile range, N number, NOS not otherwise specified, SCI-PANSS structured clinical interview for the positive and negative syndrome scale, SCZ schizophrenia and other psychotic disorders, YMRS Young mania rating scale
^aDSM-IV (American Psychiatric Association 2000)
^bDuration of treatment (months, median [IQR]): 4.0 (13.6); participants with BD: N = 82 (lamotrigine), N = 43 (valproate)
^cDuration of treatment (months, median [IQR]): 8.0 (64.3); participants with BD: N = 52
^dOf these N = 5 used lamotrigine + valproate, N = 4 used valproate + lithium, and N = 8 used lamotrigine + lithium
^eDefined as hypnotics, anxiolytics, or sedatives